Retroviruses were an attractive first choice for viral vectors for gene therapy because the DNA they encode – either wildtype viral DNA or the therapeutic transgene – becomes integrated into the host cell genome. Dr. Sophie Lutter at OXGENE outlines the challenges and changes in viral sector manufacturing when building a gene therapy.
[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/12/Building-a-Gene-Therapy.pdf” width=”100%” height=”900px” style=”border:0;”]
